Xanthohumol (Prenylated Chalcone · Metabolic · Anticancer Research)

Compound	Xanthohumol (XN; 2′,4,4′,6′-Tetrahydroxy-3′-prenylchalcone; Chalconaringenin 6′-methyl ether prenylated)
Chemical class	Polyphenol — Prenylated Chalcone (open-chain flavonoid precursor with C5 prenyl group; hops-specific)
CAS	6754-58-1
Primary source	Humulus lupulus (hops — female cone glands; highest concentration in hops of any plant)
Key applications	Metabolic syndrome; anticancer research; farnesoid X receptor (FXR) agonism; anti-obesity; antiviral
Claim strength	Moderate
Typical form	Hops Flower Extract Powder (Humulus lupulus; xanthohumol co-delivered with isoxanthohumol and 8-prenylnaringenin)
Buy from Herbuno	Hops Flower Extract Powder - Humulus lupulus →

Name origin: Xanthohumol is named after Humulus lupulus — "xantho" (yellow) referring to the golden colour of hops lupulin glands, and "humul" from Humulus. It is the most abundant prenylated flavonoid in hops female cones, concentrated in the lupulin glands alongside isoxanthohumol, 8-prenylnaringenin (8-PN), and alpha/beta hop acids. Traditional use: Hops (Humulus lupulus) has been used in European herbal medicine since the 9th century — primarily for sedation, sleep disorders, and digestive bitterness stimulation. The traditional uses relate primarily to the bitter acids (humulone, lupulone) and essential oils rather than xanthohumol specifically. Xanthohumol was identified as a significant hops constituent in the 1990s when its anticancer and metabolic properties were first characterised. Beer — which delivers isoxanthohumol (the thermal cyclisation product of xanthohumol formed during brewing) rather than xanthohumol itself — is not a significant dietary source of xanthohumol. Research trajectory: Xanthohumol has attracted research interest for metabolic syndrome (simultaneously addressing adipogenesis, insulin resistance, dyslipidaemia, and inflammation via multiple mechanisms), anticancer properties (broad cell-line antiproliferative activity at micromolar concentrations), and farnesoid X receptor (FXR) agonism (a nuclear receptor regulating bile acid, lipid, and glucose metabolism). Oregon State University has conducted multiple human clinical trials with xanthohumol preparations. Commercial source: Xanthohumol is available from Herbuno via Hops Flower Extract Powder (Humulus lupulus), which delivers xanthohumol alongside isoxanthohumol and 8-prenylnaringenin.

---

Evidence for Xanthohumol Applications

Metabolic syndrome: Xanthohumol simultaneously addresses multiple metabolic syndrome components: inhibits adipogenesis (PPARγ suppression), improves insulin sensitivity (AMPK activation), reduces lipid synthesis (SREBP-1 inhibition), lowers LDL oxidation, and reduces inflammatory cytokine production (NF-κB suppression). Oregon State University Phase II RCT (Delbaere et al. 2021) in metabolic syndrome subjects showed xanthohumol at 24 mg/day for 12 weeks improved LDL cholesterol, fasting glucose, and adipokine profiles versus placebo in a dose-dependent manner. Claim strength: Moderate.

Anticancer research: Xanthohumol demonstrates antiproliferative activity in breast, colon, prostate, and haematological cancer cell lines at 1–50 μM via: cell cycle arrest (G1/S); apoptosis induction (caspase-8/9/3 activation); angiogenesis inhibition (VEGF suppression); and reactive oxygen species-mediated cancer cell selectivity. Multiple in vivo rodent tumour studies confirm growth inhibition. Clinical cancer prevention data are not available; xanthohumol is investigated as a chemopreventive candidate. Claim strength: Emerging (clinical).

FXR (Farnesoid X Receptor) agonism: Xanthohumol activates FXR — a nuclear receptor regulating bile acid homeostasis, hepatic lipid metabolism, and intestinal innate immunity. FXR activation reduces hepatic triglyceride synthesis, improves insulin sensitivity, and reduces non-alcoholic steatohepatitis markers in rodent NAFLD models. This FXR mechanism provides a molecularly distinct basis for xanthohumol's metabolic effects complementary to its AMPK and PPAR pathways. Claim strength: Moderate (preclinical).

Antiviral: Xanthohumol has demonstrated broad-spectrum antiviral activity against HIV, cytomegalovirus, herpes simplex, and SARS-CoV-2 in cell-based assays via envelope glycoprotein binding inhibition and RdRp modulation. Claim strength: Emerging.

---

Dosage & Formulator Specification

The Oregon State University metabolic syndrome RCT used 24 mg xanthohumol/day (as a standardised XN-enriched hops extract) over 12 weeks — the most directly applicable human supplement dosing reference. Earlier studies used 10–60 mg/day ranges. Standard beer consumption provides only isoxanthohumol (not xanthohumol — which is converted by heat during brewing), not meaningful xanthohumol. Xanthohumol-enriched hops preparations (not beer) are required for supplement applications.

Hops Flower Extract from Herbuno delivers xanthohumol as part of the total hops polyphenol spectrum. For high-dose xanthohumol applications (20+ mg per serving), standardised XN-enriched hops extract (≥5% xanthohumol by HPLC) from specialty hops extract suppliers is required. Total hops polyphenol extract at typical doses (100–500 mg/day) delivers approximately 0.5–5 mg xanthohumol — below most clinical trial doses. Xanthohumol stability: the prenylated chalcone undergoes thermal cyclisation to isoxanthohumol and isomerisation to 8-prenylnaringenin on prolonged heat exposure — low-temperature extraction and nitrogen packaging are critical for xanthohumol preservation.

Xanthohumol's poor aqueous solubility (logP ~5.0) requires lipid-based delivery (softgel, SMEDDS) or cyclodextrin complexation for oral bioavailability. Plasma concentrations after standard hops extract oral administration are very low (~1–10 nM) — substantially below in vitro active concentrations. Bioavailability enhancement is the primary formulation challenge for xanthohumol's clinical translation.

No significant drug interactions are documented for xanthohumol at supplement doses. FXR agonism is pharmacologically relevant for patients on bile acid-modulating drugs or fibrates — professional monitoring is appropriate in combination use.

---

Frequently Asked Questions — Xanthohumol

Is xanthohumol present in beer?
Xanthohumol is not present in beer in meaningful quantities. During brewing, heat (boiling at 100°C for 60–90 minutes) cyclises xanthohumol's open-chain chalcone to isoxanthohumol (a flavanone) and partially to 8-prenylnaringenin. A standard pint of beer contains ~0.05–0.2 mg isoxanthohumol versus the raw hops cone's 0.5–2% xanthohumol content by dry weight. Xanthohumol supplements require non-thermal hops extraction (CO₂ extraction, cold ethanol) to preserve the intact chalcone form.

What is FXR and why is its activation by xanthohumol significant?
Farnesoid X Receptor (FXR) is a nuclear receptor expressed in the liver, intestine, and kidney — activated by primary bile acids as part of the enterohepatic bile acid feedback loop. FXR activation suppresses hepatic bile acid synthesis, reduces triglyceride production, improves insulin sensitivity, and modulates intestinal microbiome composition via antimicrobial bile acids. As a non-steroidal FXR agonist, xanthohumol potentially modulates hepatic lipid metabolism through a mechanism independent of conventional lipid-lowering pathways — of particular relevance for NAFLD/NASH formulations.

What is the relationship between xanthohumol and 8-prenylnaringenin?
Xanthohumol (chalcone) and isoxanthohumol (flavanone, its thermal cyclisation product) both serve as precursors to 8-prenylnaringenin (8-PN) via CYP1A2-mediated intestinal and hepatic O-demethylation. 8-PN is the most potent dietary phytoestrogen (higher ERα affinity than equol) and is responsible for hops preparations' oestrogenic activity. Xanthohumol itself has minimal direct oestrogenic activity — its conversion to 8-PN via isoxanthohumol is the phytoestrogen mechanism of hops preparations.

Can xanthohumol be combined with other metabolic syndrome ingredients?
Xanthohumol is compatible and potentially synergistic with: berberine (complementary AMPK activation); resveratrol (overlapping SIRT1/AMPK metabolic mechanisms); citrus PMFs — nobiletin, tangeretin (complementary PPARα activation); and milk thistle silybin (complementary hepatoprotection for NAFLD formulas). The combination of xanthohumol + berberine for metabolic syndrome represents a particularly well-rationalised mechanistic pairing for AMPK activation and lipid metabolism improvement, though no clinical trials of the specific combination have been published.

Related compounds: 8-Prenylnaringenin, Isoliquiritigenin, Butein, Phloretin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery